Tenaya Therapeutics, Inc.
Tenaya Therapeutics, Inc. (TNYA): 3 pipeline candidates · ~13 mo cash runway · 1 clinical trial. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
13.4 months
D/E 0.27 · 0% dilution
Lead: Phase 1/Phase 2
3 candidates
N/A
0 buys · 24 sells (180d)
A transparent, data-derived signal for Tenaya Therapeutics, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$154.4M
Cash
$81.3M
Quarterly Burn
$19.2M
Runway
13.4 mo
Revenue
$225K
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (3 candidates)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
100
Total value held
$37.0M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 16,964,576 | $11.7M |
| millennium management llc | 5,456,666 | $3.8M |
| citadel advisors llc | 4,376,000 | $3.0M |
| renaissance technologies llc | 3,713,761 | $2.6M |
| blackrock, inc. | 3,703,955 | $2.6M |
| marshall wace, llp | 2,705,390 | $1.9M |
| geode capital management, llc | 1,559,939 | $1.1M |
| adar1 capital management, llc | 1,507,800 | $1.0M |
| two sigma investments, lp | 1,280,390 | $887K |
| jane street group, llc | 1,224,481 | $848K |
Showing top 10 of 100 institutional holders of Tenaya Therapeutics, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Tenaya Therapeutics, Inc.'s pipeline?
Tenaya Therapeutics, Inc. (TNYA) has 3 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Tenaya Therapeutics, Inc.'s lead drug candidate?
Tenaya Therapeutics, Inc.'s most advanced tracked candidate is tn-201 (Phase 1/Phase 2) for Hypertrophic Cardiomyopathy.
What is Tenaya Therapeutics, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Tenaya Therapeutics, Inc. has approximately 13.4 months of cash runway.
What is Tenaya Therapeutics, Inc.'s market capitalization?
Tenaya Therapeutics, Inc.'s market capitalization is approximately $154.4M.
Who is the CEO of Tenaya Therapeutics, Inc.?
Mr. Faraz Ali M.B.A. is the chief executive officer of Tenaya Therapeutics, Inc. (TNYA).
Get the full picture on Tenaya Therapeutics, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.